Drug | Drug-Induced Release of [^{3}H]Neurotransmitter EC_{50} ± S.E.M. (μM) (n) % Maximum Release ± S.E.M.^{a} | ||
---|---|---|---|

hDAT [^{3}H]DA | hSERT [^{3}H]5-HT | hNET [^{3}H]NE | |

α-Pyrrolidinophenones | |||

α-PPP | >10 µM (2) | >10 µM (2) | >10 µM (2) |

−0.51 ± 2.06% | −0.58 ± 0.35% | 3.7 ± 4.3% | |

α-PBP | >100 μM (2) | >100 μM (2) | >100 μM (2) |

−1.6 ± 2.8% | 1.8 ± 1.6%^{b} | −4.1 ± 4.3% | |

α-PVP | >100 μM (2) | >100 μM (2) | >100 μM (2) |

4.5 ± 1.6% | 9.9 ± 1.5%^{b} | −1.7 ± 2.9% | |

α-PHP | >10 µM (2) | >10 µM (2) | >10 µM (2) |

1.47 ± 0.59% | 3.2 ± 3.6% | −0.5 ± 1.2% | |

PV-8 | >10 µM (2) | >10 µM (2) | >10 µM (2) |

−2.2 ± 0.73% | −0.53 ± 1.24% | 17 ± 11% | |

4-MePPP | >100 μM (2) | >100 μM (2) | >100 μM (3) |

−1.3 ± 1.7% | −2.1 ± 1.7%^{b} | 5.2 ± 2.1% | |

4-MeO-α-PVP | >9.5 (5) | >10 µM (2) | >10 µM (2) |

13 ± 12% | −0.5 ± 1.2% | 0.24 ± 0.54% | |

3,4-MDPPP | >10 µM (2) | >10 µM (2) | >10 µM (2) |

1.34 ± 0.32% | −1.12 ± 0.61% | −0.9 ± 2.7% | |

3,4-MDPBP | >10 µM (2) | >10 µM (2) | >10 µM (2) |

−0.13 ± 0.24% | 0.04 ± 0.54% | 10.2 ± 2.4% | |

α-PVT | >10 μM (2) | >10 μM (2) | >10 μM (2) |

0.88 ± 0.02% | 0.43 ± 0.14% | 4.8 ± 2.7% | |

Other substituted cathinones | |||

MCAT | 2.31 ± 0.76 (11) | 107 ± 36 (7) | 0.64 ± 0.24 (9) |

85.4 ± 6.0% | 65 ± 10% | 93.5 ± 8.2% | |

3-F MCAT | 1.29 ± 0.42 (6) | 39.0 ± 4.3 (3) | 0.13 ± 0.05 (5) |

63.3 ± 8.4% | 50.8 ± 1.4%^{b} | 96 ± 11% | |

4-Cl MCAT | 2.89 ± 0.99 (3) | 1.98 ± 0.42 (4) | 1.24 ± 0.44 (6) |

83.5 ± 6.5% | 124 ± 10% | 84.9 ± 7.0% | |

4-Br MCAT | 3.3 ± 1.1 (3) | 0.96 ± 0.13 (4) | 1.50 ± 0.63 (5) |

90 ± 13% | 131 ± 13% | 91.8 ± 6.9% | |

4-MEC | >100 μM (3) | 1.52 ± 0.42 (3) | 0.71 ± 0.20 (5) |

0.10 ± 2.0% | 99 ± 10% | 17.5 ± 4.2% | |

5-MeO-methylone | >100 μM (2) | 3.89 ± 0.41 (3) | >100 μM (2) |

2.1 ± 0.9% | 67.4 ± 2.5% | 1.6 ± 1.3% | |

Ethylone | >10 µM (2) | 1.48 ± 0.25 (4) | >10 µM (2) |

1.22 ± 0.62% | 86 ± 15%^{b} | 1.3 ± 1.7% | |

Pentedrone | >100 μM (2) | >100 μM (2) | >100 μM (2) |

4.2 ± 1.6% | 7.4 ± 2.4%^{b} | −1.1 ± 4.4% | |

Pentylone | >100 μM (2) | >100 μM (2) | >100 μM (2) |

2.4 ± 1.2% | −5.2 ± 2.1%^{b} | 4.6 ± 1.5% | |

Noncathinones | |||

MDAI | 24 ± 11 (4) | 2.9 ± 1.2 (5) | 0.57 ± 0.20 (4) |

25.0 ± 4.9% | 61 ± 12%^{b} | 68 ± 18% | |

4-FA | 1.40 ± 0.41 (5) | 11.1 ± 1.5 (4) | 0.144 ± 0.051 (5) |

96 ± 15% | 99.5 ± 6.2% | 145 ± 25% | |

METH | 0.435 ± 0.074 (13) | 23.3 ± 4.2 (10) | 0.125 ± 0.024 (8) |

101.3 ± 2.9 | 93.0 ± 7.5% | 102.6 ± 3.0% | |

MDMA | 7.5 ± 2.3 (10) | 1.10 ± 0.29 (9) | 0.360 ± 0.092 (7) |

94 ± 10% | 85.1 ± 7.8% | 147 ± 15% | |

PCA | 1.25 ± 0.34 (6) | ||

105.5 ± 1.6%^{b} |

*n*, number of independent experiments.↵

Maximum release is defined as the maximum release (maximal AUC) induced by METH (1 or 10^{a}*μ*M, hDAT; 0.3 or 1*μ*M, hNET; 0.3–1 mM, hSERT) for each experiment.↵

Maximum release is defined as the maximum release (maximal AUC) induced by p-chloroamphetamine (PCA, 10^{b}*μ*M, hSERT) for each experiment.